This image is not available for purchase in your country.

Antibody acting against tumour cell

Antibody acting against tumour cell

C029/0094

Rights Managed

This image is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

ALFRED PASIEKA / SCIENCE PHOTO LIBRARY ALFRED PASIEKA / SCIENCE PHOTO LIBRARY

Caption

Computer artwork of monoclonal antibodies, bi-specific T-cell engagers (BiTEs), acting against tumour cells. Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.Blinatumomab is used as a second-line treatment against acute lymphoblastic leukemia. The image shows a cancer cell (red, down left) and an immune cell (blue, upper right) connected by the Blinatumomab bi-specific antibody.

Release details

Model release not required. Property release not required.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Add to board
  • Similar {{ mediaType(i) }}